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Abstract
Although the accessibility of HIV treatment in developing nations has increased dramatically over the past decade, viral load
testing to monitor the response of patients receiving therapy is often unavailable. Existing viral load technologies are often
too expensive or resource-intensive for poor settings, and there is no appropriate HIV viral load test currently available at
the point-of-care in low resource settings. Here, we present a lateral flow assay that employs gold nanoparticle probes and
gold enhancement solution to detect amplified HIV RNA quantitatively. Preliminary results show that, when coupled with
nucleic acid sequence based amplification (NASBA), this assay can detect concentrations of HIV RNA that match the clinically
relevant range of viral loads found in HIV patients. The lateral flow test is inexpensive, simple and rapid to perform, and
requires few resources. Our results suggest that the lateral flow assay may be integrated with amplification and sample
preparation technologies to serve as an HIV viral load test for low-resource settings.
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Introduction
Over two-thirds of the 33.3 million people estimated to be
infected with HIV worldwide live in the developing world [1]. In
response to the HIV/AIDS crisis, access to anti-retroviral therapy
(ART) has increased dramatically over the past decade in low- and
middle-income countries [2]. However, successful management of
HIV requires that patients receiving ART be monitored routinely
to assess treatment efficacy and detect treatment failure due to
drug resistance. Unfortunately, current laboratory based methods
to monitor ART are unaffordable, unavailable, or inappropriate
for low-resource settings [3].
Rapid antibody tests are widely available in developing nations,
but they cannot be used to monitor HIV progression or treatment
efficacy. The standard of care to monitor ART is quantitative viral
load testing based on plasma HIV RNA concentration [4].
Although CD4 count has also been used to monitor ART, recent
studies suggest that it may not detect early treatment failure
adequately [5]. The gold standard method for viral load testing,
RT-qPCR, is unsuitable for settings where trained technicians,
expensive reagents, electrically powered equipment, and dedicated
laboratory space are often unavailable. Therefore, a viral load test
that is appropriate for such settings is needed.
A number of commercially available viral load tests have been
developed for use at the point-of-care but suffer from drawbacks
that limit their widespread implementation [6–8]. Many emerging
technologies that are better designed for use in developing
countries may serve as improved point-of-care viral load tests. A
variety of microfluidic systems have been developed to perform
nucleic acid amplification on-chip [9–11]. However, microfluidic
systems often require a syringe pump for operation and additional
imaging equipment to acquire results. To avoid the difficulties
associated with enzymatic amplification of target RNA, alternative
approaches have attempted to improve the sensitivity of nucleic
acid detection through signal amplification [12,13]. Other
researchers have developed quantitative tests for p24 antigen
[14,15], which may serve as a surrogate for HIV viral load [7].
Despite these advances, no appropriate point-of-care HIV viral
load test is currently available.
Recently, paper-based devices have shown promise as point-of-
care diagnostics because paper is inexpensive, portable, disposable
by burning, and has the ability to wick fluids by capillarity [16].
The emergence of paper microfluidics has renewed interest in
lateral flow tests, which have served as point-of-care tests for
decades. For example, recent work has shown that lateral flow tests
may achieve a greatly improved limit of detection (LOD) and serve
as platforms for multiplexed detection [13,17,18]. Still, most
examples of paper microfluidic technology are antibody tests or
small molecule tests [19–22], and much work remains to be done
to develop and improve paper-based nucleic acid tests.
Here we present a quantitative lateral flow test for detecting
amplified HIV RNA that is appropriate for low-resource settings.
Gold nanoparticles conjugated to complementary oligonucleotides
are used as probes, and gold enhancement is implemented to
improve the LOD. Our results indicate that this lateral flow assay
may be used in conjunction with amplification to detect HIV RNA
concentrations at clinically meaningful levels.
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Methods
Lateral Flow Assay (LFA) Development
The LFA was designed to quantitatively detect amplified HIV-1
RNA (Fig. 1). When RNA is dispensed onto the conjugate pad of
the strip, the RNA binds to complementary oligonucleotides
conjugated to gold nanoparticle probes (GNPs). The target RNA –
GNP complex flows down the strip via capillarity and is captured
by the target capture sequence in the center of the strip. Unbound
GNPs bind to the positive control sequence at the end of the strip.
A wash buffer carries unbound GNPs down the strip to decrease
the background, while an enhancement solution increases the size
and optical absorbance of the bound GNPs. The LFA was
designed so that the number of GNPs captured in the detection
zone would likely be proportional to the number of RNA copies
dispensed onto the strips, providing a quantitative detection
modality.
Because the concentration of HIV found in patient plasma
samples can be as low as a few copies per milliliter, nucleic acid
amplification of genomic HIV RNA must be performed prior to
detection with the LFA. The LFA was designed to detect a 142 bp
NASBA product amplified from the HIV gag gene. To develop and
optimize the LFA, we used a 179 bp synthetic RNA sequence
containing the NASBA product sequence (Table 1). The synthetic
RNA sequence was generated through in vitro transcription using
the MEGAscript T7 kit (Applied Biosystems) and a plasmid
containing the T7 promoter upstream of the template sequence
(pIDTBlue, Integrated DNA Technologies). The in vitro transcrip-
tion reaction products were purified using an RNeasy column
(QIAGEN, RNeasy Cleanup Protocol) and quantified by measur-
ing absorbance at 260 nm.
Quantitative Analysis of LFA Performance
For all experiments, the performance of the LFA was assessed
quantitatively using image analysis. All LFA strips were scanned
(Epson Perfection V500 Photo) and imaged using a stereo
microscope (Olympus SZ61) equipped with a color camera (Zeiss,
AxioCam MRc5). Images obtained with the stereo microscope
were analyzed using a custom Matlab script. The green channel
image was cropped to rectangular field-of-view including the
captured GNPs and surrounding strip area. An intensity threshold
was set by the user to make a mask, which segmented the GNP
spot from the background. For images with a high noise level, the
mask was drawn manually using the function ‘roispline’ (Math-
works). The intensity of each pixel was subtracted from 255 in
order to invert the image data, and the signal-to-background ratio
(SBR) was calculated. LFA results are expressed using the SBR.
LFA Optimization Experiments
The LFA was developed to achieve the best LOD and dynamic
range possible while remaining appropriate for low resource
settings. We aimed to design a test that costs less than $1, requires
an assay time of less than 30 minutes, detects RNA in a volume of
less than 50 mL, requires minimal instrumentation, and remains
stable for months at ambient temperature. The conditions that
were optimized included capture oligonucleotide sequence and
concentration, buffer composition, nitrocellulose flow rate, strip
width, and gold nanoparticle size (Table 2). To maximize the
signal generated by the GNPs, gold and silver enhancement were
explored for signal amplification. During gold and silver
enhancement, metallic ions are reduced on the surface of the
GNPs, increasing their size and optical extinction in order to
improve the limit of detection (LOD) of the assay [17,23].
For the optimization experiments, the LFA was performed using
a dilution series of in vitro transcribed target RNA for each
condition to be optimized. The SBR of the detection zone was
calculated for each LFA. The SBR was normalized to a maximum
value of 100 for each RNA target concentration. Average
normalized SBRs for each condition were used to compare
conditions. The optimum conditions were defined as those that
maximized the SBR, affording the best LOD and largest dynamic
range.
Fabrication of LFA Strips using Optimized Parameters
For all subsequent experiments, LFA strips were fabricated
using the optimized parameters. Gold nanoparticles were chosen
as probes because of their large optical cross-section and stability
[24]. Gold nanoparticle probes (GNPs) were made by conjugating
thiolated oligonucleotides (Integrated DNA Technologies) to gold
nanoparticles (Ted Pella, NanoXact tannic acid capped gold
colloid). The 35 bp oligonucleotide probe sequence contained an
18-atom hexa-polyethyleneglycol internal spacer and 15 bp polyA
spacer to maximize loading of oligonucleotides onto the gold
nanoparticles (Table 1) [25]. The oligonucleotides (25 mL,
0.1 mM) were incubated for 30 minutes with TCEP-HCl
(10 mL, 100 mM) in a total volume of 110 mL to reduce the
dithiol bonds. A 600 mL volume of 60 nm gold colloid at the
supplied concentration was added to the reaction and incubated
overnight on a rotisserie. A 3.57 mL volume of 2% SDS was added
to the reaction to reach a final SDS concentration of 0.01%. After
30 minutes of incubation, five 11.57 mL volumes of 2 M NaCl
were added to the solution, separated by 2-hour intervals, to reach
a total NaCl concentration of 0.15 M. The following day, the
GNPs were centrifuged (5000 rcf for 5 minutes) and washed four
times with 1 mL of 0.15 M NaCl, 0.01% SDS. The GNPs were
resuspended in GNP buffer (0.15 M NaCl, 5% BSA, 0.25%
Tween, 10% sucrose) after the final wash.
LFA strips were assembled using glass fiber conjugate pads,
nitrocellulose cards, and cellulose absorbent pads. Conjugate pads
were cut into 1 cm by 0.5 cm rectangles from glass fiber sheets
(GFCP203000, Millipore) using a 60-watt laser cutter (Universal
Laser Systems) with 3% power and 5% speed. Ten microliters of
GNPs were dispensed onto each pad and dried at room
temperature before strip assembly. Absorbent pads (CFSP223000,
Millipore) and nitrocellulose strips with a plastic backing (Hi-Flow
Figure 1. Lateral flow assay design. The lateral flow assay is
designed to detect a 142 bp amplified RNA sequence. The lateral flow
strip consists of a conjugate pad containing gold nanoparticle probes
(GNPs), a nitrocellulose membrane containing capture oligonucleotides,
and an absorbent pad. Target RNA is dispensed onto the conjugate pad
and binds to the GNPs. The target RNA – GNP complex flows down the
strip and binds to the target capture sequence, while unbound GNPs
bind to the positive control sequence. After wash buffer carries
unbound GNPs down the strip, an enhancement solution is added to
increase the optical absorbance of the captured GNPs. The signal of the
GNPs captured in the detection zone should be proportional to the
number of RNA copies dispensed onto the strip, providing quantitative
detection.
doi:10.1371/journal.pone.0045611.g001
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135, Millipore) were cut using a guillotine cutter (A-Point
Guillotine Cutter Digital Model, Arista Biologicals). Nitrocellulose
strips were 3 mm wide, and absorbent pads were cut into
1 cm60.75 cm rectangles.
Two oligonucleotide sequences were dispensed onto the
nitrocellulose strip (0.2 mL volume, 0.4 mM concentration). The
target capture sequence, which is complementary to a region of
the target RNA sequence, was dispensed in the center of the strip;
the positive control sequence, which is complementary to the
probe sequence conjugated to the GNPs, was dispensed near the
end of the strip (Table 1). After the oligonucleotide solutions dried
on the strip at room temperature, strips were exposed to UV light
(UVP HL-2000 HybriLinker) at 125 mJ/cm2 to crosslink the
oligonucleotides to the nitrocellulose. Conjugate and absorbent
pads were placed on the adhesive at opposite ends of the
nitrocellulose strip, overlapping the nitrocellulose by approximate-
ly 2 mm. Strips were used immediately or stored in foil pouches
(Clonesaver Resealable Multi Barrier Pouch, Whatman) with
desiccant (FTA Card Desiccant Packet, Whatman).
Characterization of the LFA
After the LFA was optimized, the assay was evaluated for use as
a quantitative detection platform. The consistency of LFA
performance was tested on two different days. On the first day,
one batch of LFA strips was fabricated and the assay was
performed in duplicate; on the second day, a second batch of LFA
strips was made and the assay was performed in triplicate. Serial
dilutions of the in vitro transcribed target RNA were used to assess
LFA performance. The RNA was prepared in 20 mL of running
buffer (4x SSC with 5% formamide) and dispensed onto the
conjugate pad of the lateral flow strip. After a 10 minute
incubation on a heat block at 37uC, 30 mL of wash buffer (1x
SSC) was dispensed onto the conjugate pad and incubated an
additional 10 minutes at 37uC. During incubation, gold enhance-
ment solution was prepared by mixing equal volumes of initiator,
buffer, activator, and enhancer solutions (Nanoprobes, Gold
Enhance LM/Blot). For experiments using silver enhancement,
equal volumes of blotting initiator and blotting enhancer were
mixed (Ted Pella, Silver Enhancing Kit). Enhancement was
performed by adding 30 mL of enhancement solution to the
conjugate pad of the strip. LFA strips were left at room
temperature to dry. LFA strips were imaged using a flatbed
scanner and a stereo microscope and analyzed using the Matlab
script as described previously. Dose response curves were
constructed to characterize the LFA based on the average
signal-to-background ratio calculated for each concentration.
Because the LFA must perform consistently over time in order
to be used as a point-of-care test, the stability of the assay was
assessed after storing the strips and necessary reagents. At the
beginning of the stability study, all lateral flow strips were
fabricated on the same day and placed in foil pouches with
desiccant. Half of the strips were incubated in an oven at 37uC;
half of the strips were kept at room temperature. All buffers and
reagents, including gold enhancement reagents, were prepared
and set at room temperature for the duration of the study. The
lateral flow assay was performed and analyzed on the day of strip
creation and 1, 3, 7, 14, 21, and 28 days after strip creation. The
two sets of strips tested on the day of fabrication were also used to
assess LFA consistency (described in the previous paragraph). Dose
response curves for each time point were constructed to assess the
performance of the LFA over time.
Detection of NASBA Products
To demonstrate that the LFA may serve as a detection platform
in an HIV-1 viral load assay, NASBA was performed to generate
reaction products for detection on LFA strips. A plasmid
containing the HIV gag sequence (pNL43) served as the template
for in vitro transcription to generate synthetic copies of HIV gag
RNA (MEGAscript T7 kit, Applied Biosystems). Zero, 5, 50, 500,
and 5000 copies of gag RNA served as samples for NASBA
reactions.
An additional control of nonspecific, genomic nucleic acid was
included in some experiments to demonstrate the specificity of our
assay. For this control, total nucleic acid was purified from
cultured lymphoblasts (CCRF-CEM cells, American Type Culture
Collection) using the QIAamp DNA Blood Mini kit (Qiagen). A
total of 740 ng of purified nucleic acid served as a sample for
NASBA. To further ensure specificity, we designed the LFA target
capture and probe sequences to bind to the amplified sequence
between the regions targeted by the NASBA primer sequences.
Therefore, any sequence amplified as a result of mispriming
should not be detected by the LFA.
In four experiments, NASBA products were generated and
detected using the LFA. NASBA was performed using the
NucliSens EasyQ Basic Kit as described by the manufacturer
(bioMe´rieux). The KCl concentration in each reaction was
36 mM. Primers NASBAp5 and NASBAp6 as well as the NASBA
product sequence are shown in Table 1. Briefly, NASBA reactions
were denatured for 4 min. at 65uC, incubated for 4 min. at 41uC,
Table 1. Sequences used for lateral flow assay and NASBA.
Function Name Sequence
Synthetic target sequence for LFA IVTX1 59-GGCGAATTGGGTACGATCGATGCGGCCTCCTCGAGTGCTATGTCACTTCCCCTTGGTTCTCTCATCTG
GCCTGGTGCAATAGGCCCTGCATGCACTGGATGCAATCTATCCCATTCTGCAGCTTCCTCATTGATGGTC
TCTTTTAACATTTGCATGGCTGCTTGATGTCCCCCCACTG-39
Probe oligonucleotide on GNPs GNP6B 59-CAGAATGGGATAGATTGCAT/PEG18/AAAAAAAAAAAAAA/SH-39
LFA target capture sequence CPT1C 59-GACCATCAATGAGGAAGCTG-39
LFA positive control sequence POS1 59-ATGCAATCTATCCCATTCTGTTT-39
Forward primer for NASBA NASBAp5 59-aattctaatacgactcactatagggCTATGTCACTTCCCCTT-39
Reverse primer for NASBA NASBAp6 59-CATCAAGCAGCCATGCAA-39
NASBA product sequence NBPRD1 59-TGCTATGTCACTTCCCCTTGGTTCTCTCATCTGGCCTGGTGCAATAGGCCCTGCATGCACTGGATGCA
ATCTATCCCATTCTGCAGCTTCCTCATTGATGGTCTCTTTTAACATTTGCATGGCTGCTTGATGTCCCCCC
ACT-39
doi:10.1371/journal.pone.0045611.t001
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and then allowed to proceed for 90 min. at 41uC after the addition
of enzyme. All incubation steps were performed using a heat block.
NASBA products consisted of a 142 bp sequence and were diluted
by a factor of 10, 100, or 1000 in running buffer. Twenty
microliters of diluted products were dispensed onto LFA strips for
detection, followed by the wash and enhancement steps as
previously described. Dose response curves were made to assess
the LFA results.
Results
Development and Optimization of the LFA
The LFA was developed and optimized to provide quantitative
detection of RNA for eventual use as part of an HIV-1 viral load
test. The assay parameters shown in Table 2 were found to
optimize performance of the LFA while maintaining conditions
that are achievable in low resource settings. The parameters that
most affected the LFA performance were capture oligonucleotide
concentration, gold nanoparticle size, buffer composition, and
temperature. Performing the assay at 37uC on a heat block
eliminated any nonspecific binding of GNPs at the detection zone,
which is important for avoiding false positive results. Gold and
silver enhancement provided signal amplification by increasing the
signal-to-background ratio of the detection zone, thereby improv-
ing the LOD. Gold enhancement increased the signal-to-
background ratio (SBR) by ,25%, while silver enhancement
increased the SBR by ,15%. LFA strips that underwent silver
amplification resulted in a high background, while gold enhance-
ment did not significantly affect the background. Therefore, gold
enhancement was chosen for signal amplification in later
experiments.
LFA Performance and Stability
The performance of the LFA demonstrates that the assay can
serve as a quantitative detection platform. Figure 2a shows a
scanned image of one set of LFA strips after the assay was
performed using various concentrations of target RNA. Figure 2b
shows dose response curves for two batches of LFA strips made
and tested on different days. The dose response curves are based
on the average SBR calculated for each concentration. For Batch
1, the dynamic range extended 2.5 orders of magnitude, from 10.5
to 13 log10 RNA copies. The linear region of the dynamic range
extended 1.5 orders of magnitude, from 11 to 12.5 log10 RNA
copies. The LOD, which we define as the first concentration for
which the SBR is significantly different from the negative control
SBR (p,0.05), was 10.5 log10 RNA copies. For Batch 2, the
dynamic range extended 3.5 orders of magnitude, from 9.5 to 13
log10 RNA copies. The linear region of the dynamic range
extended 2.5 orders of magnitude, from 10.5 to 13 log10 RNA
copies. The LOD was 9.5 log10 RNA copies (p,0.05).
The linear range was slightly larger and the LOD was lower for
Batch 2 than Batch 1. This difference in performance could be
explained by batch-to-batch differences in the preparation of LFA
strips, as we have observed some variability in the efficiency of the
oligo loading on GNPs (data not shown). Importantly, we did not
observe this variability between strips of the same batch.
Therefore, a standard curve may be constructed to calibrate the
LFA and to account for batch-to-batch performance variability.
After storing a single batch of LFA strips for various periods of
time at room temperature and 37uC, the performance of the assay
remained consistent (Fig. 3). The dose response curves for each
day (Fig. 3a and 3c) show that there is no trend in assay
performance variability over time. Furthermore, no significant
difference was observed between the average performance of strips
stored at room temperature (Fig. 3b) and at 37uC
(Fig. 3d).Throughout the time course for both storage conditions,
the LOD was 9.5 log10 RNA copies, and the linear dynamic range
extended from 10.5 to 13 log10 RNA copies. Average SBRs for
each pair of adjacent concentrations were compared using t-tests,
which yielded p-values less than 0.05 for all but one pair (p = 0.07
for 12.5 and 13 log10 RNA copies for strips stored at 37uC). Thus,
the resolution of the assay regardless of storage conditions was 0.5
log10 RNA copies. These results demonstrate that the assay
performs consistently even after short-term storage, suggesting that
Table 2. Optimized experimental conditions for the lateral flow detection assay.
Experimental condition Values tested Optimum value
Capture oligo concentration 0.1, 0.2, 0.4, 0.6 mM 0.4 mM
Type of running buffer 4X SSC; 4X SSC with 5% formamide; 4X SSC with 5%
formamide, 1.4% Triton X-100, and 1% SDS
4X SSX with 5% formamide
Ratio of detection sequence to random sequence on GNPs 1:0, 3:1, 1:1, 1:3 1:0
Nitrocellulose flow rate 75, 135, 180 s/4 cm 135 s/4 cm
Gold nanoparticle size 15, 30, 50, 60, 70, 80 nm 50 or 60 nm
Gold nanoparticle orientation 5¢ or 3¢ end of probe 3¢ end of probe
Capture probe length 16 and 20 bp 20 bp
Ratio of detection probe to polyA spacer on GNPs 1:0, 9:1, 3:1, 1:1, 1:3 1:0
Detection probe sequence Sequence adjacent to capture probe, seq. 20 bp away from
capture probe
Adjacent sequence
Ionic strength of wash buffer 0.1, 0.25, 0.5, 2, 4, 10X SSC 0.5X SSC
Time to incubate GNP probes and RNA target 0, 5, 15, 30 min. 0 min.
Ionic strength of running buffer 0.5, 1, 2, 4X SSC 4X SSC
Formamide concentration of wash buffer 0, 5, 10, 20% formamide 0% formamide
Lateral flow strip width 2, 3, 4, 5 mm 2 or 3 mm
Temperature Room temp., 37uC, 42uC, 46uC 37uC
doi:10.1371/journal.pone.0045611.t002
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the LFA may be used in settings where the storage conditions of
test strips may vary greatly.
Detection of NASBA Products
NASBA products were detected using the LFA to demonstrate
that the LFA can detect amplified target RNA. The upper limit of
the clinical range for HIV-1 viral load is about 6 log10 copies/mL,
while the LFA has an LOD of 9.5 log10 RNA copies in 20 mL
(equivalent to ,11 log10 copies/mL). Therefore, NASBA was
chosen to amplify HIV-1 RNA because NASBA is a well-
established isothermal method that provides 10 to 12 orders of
magnitude of amplification [26].
The LFA was used to detect NASBA products in four different
experiments. Figure 4a shows the LFA strips for one experiment,
in which NASBA products generated from 50, 500, and 5000
copies of gag RNA were detected by lateral flow strips after dilution
by a factor of 10, 100, and 1000 in running buffer. A dilution
factor of 100 was sufficient for the SBR to fall within the linear
range of the LFA. Figure 4b demonstrates the linear relationship
between the SBR and amount of template gag RNA (R2= 0.93).
The R2 values for all four experiments range from 0.90–0.98 with
a mean value of 0.94, indicating that the LFA detects amplified
RNA quantitatively (Fig. S1). However, the equations of the
regression lines differ for each experiment, which suggests that the
performance of NASBA varies from day to day. A standard curve
should be constructed for each experiment to correct for this
variation. The LOD for all four experiments was at least 50 copies,
and no signal was present on LFA strips for any of the no-target
controls or samples containing background nucleic acid (Fig.
S1).Therefore, when combined with NASBA, the LFA may
potentially report gag RNA concentrations that fall within the
clinical range with adequate specificity.
Discussion
Ideally, HIV viral load is measured before a patient initiates
ART and throughout the course of treatment. Typically, patients
who begin to experience symptoms have plasma viral load levels
exceeding 10,000 viral copies/mL [27]. After ART is initiated,
patients are monitored for a significant change in viral load, which
is defined as a three-fold or 0.5 log10 copies/mL change. After 4–8
weeks, ART is considered to be efficacious if viral load decreases
by 1.0 log10 copies/mL [28,29]. Suppression of viral replication is
considered successful if the viral load falls below 200 copies/mL
[29]. Therapeutic failure due to drug resistance is characterized by
a return of low-level viremia, which is defined as a viral load of at
least 500–1000 copies/mL [4]. A point-of-care viral load test
should achieve an LOD and resolution that accurately identifies
these clinical benchmarks.
The lateral flow assay presented here achieves a resolution of
0.5 log10 copies/mL over a linear range that extends 2.5 orders of
magnitude. When coupled with NASBA, the LFA can detect 50
copies of HIV gag RNA. We speculate that this LOD corresponds
to a plasma viral load of roughly 1000 copies/mL, assuming that a
plasma sample volume of 100 mL will be used and that half of viral
RNA from the sample is added to the NASBA reaction. The
performance of the LFA when detecting NASBA products suggests
that the LFA may be sufficient to detect significant changes in viral
load, suppression of viral replication, and therapeutic failure. The
LFA only requires a heat block, scanner or camera, and pipette.
The lateral flow assay uses a sample volume of 20 mL, requires
only three steps over the course of 20 minutes, costs $0.80 per strip
using commercial reagents, and performs consistently after short-
term storage. By modifying the target capture, positive control,
and probe sequences, the LFA may be adapted to detect other
RNA targets. The LFA is capable of detecting short, amplified
sequences or long, genomic sequences, although the LOD may
increase with target size by an order of magnitude or more (data
not shown). The LFA is suitable for low-resource settings and has
the potential to be performed at the POC.
The LFA represents a different approach from other assays that
may potentially serve as viral load tests. While other researchers
have developed quantitative tests for p24 antigen to avoid the
complications of nucleic acid tests [14,15], the LFA detects HIV
Figure 2. Performance of the optimized lateral flow assay.
Lateral flow strips were made and tested on two different days (Batch1
and Batch2). The lateral flow assay was performed in duplicate (Batch1)
or in triplicate (Batch2) using a dilution series of in vitro transcribed
RNA. The number of RNA copies dispensed per strip ranged from 9.5 to
13 log10 copies in steps of 0.5 log10 copies. (A) Scanned image of one
set of lateral flow strips. Note that although the contrast was adjusted
in the figure, raw images were used for signal-to-background
calculations. (B) Dose response curves based on the average signal-
to-background ratio (SBR) for each log10 copy number. The negative
control SBR is shown for comparison. Error bars represent one standard
deviation. The line and regression equation are shown to denote the
linear range of the assay.
doi:10.1371/journal.pone.0045611.g002
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RNA, which is the traditional target for viral load tests. Like other
lateral flow tests that use signal amplification to achieve
appropriate sensitivity [12,13], the LFA presented here uses gold
enhancement to improve performance. However, because the
LFA provides detection of nucleic acids after target amplification,
the LFA may be used with any amplification method that
generates RNA. For example, the LFA may be used in
conjunction with microfluidic systems that have been designed
to perform nucleic acid amplification [9,10]. Therefore, the LFA
may be integrated with new or existing amplification systems to
measure HIV viral load.
Although the LFA performs well for detecting amplified HIV
RNA, some of the required conditions may be difficult to achieve
at the point-of-care. Currently, the LFA requires a heat block,
which may be unavailable in low-resource settings because of cost
and the requirement for electricity. To overcome these obstacles,
the LFA may be used in conjunction with an inexpensive battery-
powered heater or exothermal chemical heating unit based on
engineered phase change materials [30,31]. Another drawback of
the LFA is that strips are left to dry before the data are collected,
which requires additional time. In order to decrease the total assay
time, strips may be dried quickly by heating or imaged while wet.
In this study strips were imaged with a microscope, which often is
not available in the field. To eliminate the necessity of expensive
imaging equipment, strips may be imaged with a digital camera,
point-of-care optical reader, or cell phone [32,33]. Alternatively,
the color of the detection zone may be compared to a color scale to
completely eliminate the need for imaging equipment. Finally, the
LFA requires multiple pipetting steps and a dilution series of
standards to achieve quantitative results; other work has shown
that multi-step assays may be integrated in a paper microfluidic
device to simplify the procedure and avoid the need for a pipette
Figure 3. Performance of the lateral flow assay after storage. To assess the effects of storage on LFA performance, lateral flow strips were
fabricated on the same day, placed in foil pouches with desiccant, and stored at room temperature or 37uC. The lateral flow assay was performed and
analyzed on the day of strip creation and 1, 3, 7, 14, 21, and 28 days after strip creation. The signal-to-background ratio (SBR) for each log10 copy
number is shown for strips performed on different days. The negative control SBR is shown for comparison. The regression line and equation were
calculated for the average SBRs over the linear range of the assay, from 10.5 to 13 log10 RNA copies. (A) Dose response curves at each time point and
(B) average dose response curve for strips stored at room temperature. (C) Dose response curves at each time point and (D) average dose response
curve for strips stored at 37uC.
doi:10.1371/journal.pone.0045611.g003
Lateral Flow Assay for Detecting Amplified HIV RNA
PLOS ONE | www.plosone.org 6 September 2012 | Volume 7 | Issue 9 | e45611
[34]. Despite current limitations, the LFA may be modified or
used in conjunction with other available technology to serve as an
appropriate point-of-care test. Further work would be required to
integrate the LFA with sample preparation and nucleic acid
amplification in a format that is suitable for low resource settings.
We have described a quantitative LFA that detects amplified
HIV RNA by using gold nanoparticle probes and gold enhance-
ment. The assay has the potential to serve as part of a point-of-care
test in low-resource settings. Because this assay serves as a
detection platform, the LFA that may be adapted to quantify RNA
targets for other diseases as well. The LFA may be integrated with
amplification and sample preparation to comprise an HIV viral
load test for low-resource settings. Point-of-care tests for viral load
measurement in low resource settings have the potential to allow
proper monitoring of HIV patients receiving ART, improving the
management of HIV in the developing world.
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Figure S1 Detection of NASBA products in three addi-
tional experiments (A–C). To the left, scanned images of LFA
strips are shown at the appropriate dilution for the SBRs to fall
within the linear range of the assay. The total number of gag RNA
copies added to each NASBA reaction are shown next to each
image. Note that although the contrast was adjusted for scanned
images, raw images were used for signal-to-background calcula-
tions. To the right, the SBRs for the LFA strips are shown.
‘NTC’= ‘no target control.’ An asterisk (*) denotes that 740 ng of
total nucleic acid purified from lymphoblasts was added to the
sample.
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